Abstract： Objective　To understand the new HIV-1 infection in MSM (men who have sex with men) sentinel population in Haikou and explore the influencing factors of HIV/AIDS epidemic, so as to provide a basis for AIDS prevention and control. Methods　A continuous cross-sectional study was used to detect HIV-1 infection in the MSM sentinel surveillance population in Haikou City from 2019 to 2023, excluding those with known past positive results and those who had been on antiretroviral therapy for more than six months. The positive cases suitable for new infection testing were examined by HIV-1 restriction antigen affinity enzyme immunization method, and binary non-conditional logistic regression model conducted multivariate analysis of new infections. Results　A total of 2 001 MSM were recruited, with a median age M（P25, P75）of 28 (23, 33) years, 89.8% were recruited from the Internet, 90.8% were single; 79.7% resided in the local area for >2 years, 72.6% were educated to college level or above, and the proportion of household registration in the province was 78.0%. From 2019 to 2023, the HIV-1 positive rate among MSM in Haikou from 2019 to 2023 was 6.85% (137/2 001), with a new infection rate of 2.95% (59/2 001). The estimated new infection rate was 8.61% (95%CI: 6.41-10.81), with no significant trend changes in HIV-1 positivity and new infection rates over the years (P>0.05). Multivariate analysis revealed that, compared to those who lived locally for ≤2 years, those residing locally for >2 years had a lower probability of recent HIV-1 infection (OR=0.473，95%CI: 0.273-0.821). Compared to those who had never received intervention services, those who had received such services had a lower risk of recent HIV-1 infection (OR=0.347, 95%CI:0.197-0.613). Conclusions　In recent years, the Haikou MSM population has shown characteristics of higher education and younger age, and the rate of new HIV-1 infections has not changed significantly. Receiving intervention services is the protection factor to prevent HIV-1 new infections, whereas the mobile MSM population has a higher risk of HIV-1 new infection. Health management of the mobile MSM population should be strengthened to expand the coverage of AIDS intervention services.

Objective To observe the clinical effects and safety of sodium valproate combined with decitabine for treatment of myelodysplastic syndrome (MDS). Methods Forty-two patients with MDS were enrolled in department of hematology in Shanxi Dayi Hospital from February 2012 to February 2017. According to random number table, the patients were divided into the control group (21 cases) and the experimental group (21 cases). The patients in the control group received decitabine at the dose of 20 mg·m-2·d-1, and intravenous infusion was completed in 2 hours, continuous therapy up to 5 days, 4 weeks as a course; the patients in the experimental group received combined medication, orally given sodium valproate 0.2 g once, 3 times per day. One week later, the dosage was added to 0.4 g once, 3 times per day. Both groups received at least 4 courses of treatment. The treatment was stopped when serious adverse reactions or obvious disease progression occurred. The bone marrow smear was rechecked every 4 weeks after treatment to evaluate the efficacy. The expressions of ASXL1, DNMT3A and TET2 in bone marrow cells were detected by fluorescence quantitative PCR before and after treatment. Results The total treatment response rate of the experimental group and the control group were 76.2 % (16/21) and 57.1 % (12/21) respectively, and there was statistically significant difference (P< 0.05); the total remission rate of the two groups was 47.6 % (10/21) and 38.1 %(8/21) respectively, and there was no significant difference (P> 0.05). All patients had slight adverse reactions, and the adverse reaction rate was 42.9 % (9/21) and 38.1 % (8/21), and there was no significant difference (P>0.05). The content of TET2 mRNA and DNMT3A mRNA after treatment in both groups were decreased compared with the expressions before treatment, and there were significant differences (P<0.05). However, there was no significant difference between the two groups after treatment (P> 0.05); the content of ASXL1 mRNA had no obvious change in the control group and a dramatic decrease in the experimental group compared with that before treatment (P<0.05). Conclusion Sodium valproate combined with decitabine has favorable effects and mild adverse reactions for treatment of MDS, besides, it can influence the expressions of TET2, DNMT3A and ASXL1.